Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 3/2020

02.01.2020 | Original Article

Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment

verfasst von: Pazit Salamon, Yoseph A. Mekori, Irit Shefler

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Activated mast cells are often found in the tumor microenvironment. They have both pro- and anti-tumorigenic roles, depending on the tumor type. Several lines of evidence suggest that the tumor microenvironment contains multiple soluble factors that can drive mast cell recruitment and activation. However, it is not yet clear how mast cells are activated by tumor cells. In this study, we explored whether tumor-derived microvesicles (TMV) from non-small cell lung cancer (NSCLC) cells interact with human mast cells, activate them to release cytokines, and affect their migratory ability. PKH67-labelled TMV isolated from NSCLC cell lines were found to be internalized by mast cells. This internalization was first noticed after 4 h and peaked within 24 h of co-incubation. Furthermore, internalization of TMV derived from NSCLC cell lines or from surgical lung tissue specimens resulted in ERK phosphorylation, enhanced mast cell migratory ability and increased release of cytokines and chemokines, such as TNF-α and MCP-1. Our data are thus, consistent with the conclusion that TMV have the potential to influence mast cell activity and thereby, affect tumorigenesis.
Literatur
4.
Zurück zum Zitat Dyduch G, Kaczmarczyk K, Okon K (2012) Mast cells and cancer: enemies or allies? Pol J Pathol 63(1):1–7PubMed Dyduch G, Kaczmarczyk K, Okon K (2012) Mast cells and cancer: enemies or allies? Pol J Pathol 63(1):1–7PubMed
17.
Zurück zum Zitat Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA (2001) Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol (Baltimore, MD: 1950) 167(7):4008–4016CrossRef Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA (2001) Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol (Baltimore, MD: 1950) 167(7):4008–4016CrossRef
21.
25.
Zurück zum Zitat Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, Ratajczak MZ, Zembala M (2006) Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother CII 55(7):808–818. https://doi.org/10.1007/s00262-005-0075-9 CrossRefPubMed Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, Ratajczak MZ, Zembala M (2006) Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother CII 55(7):808–818. https://​doi.​org/​10.​1007/​s00262-005-0075-9 CrossRefPubMed
27.
31.
Zurück zum Zitat Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27(8):677–682CrossRef Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27(8):677–682CrossRef
Metadaten
Titel
Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment
verfasst von
Pazit Salamon
Yoseph A. Mekori
Irit Shefler
Publikationsdatum
02.01.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 3/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02459-w

Weitere Artikel der Ausgabe 3/2020

Cancer Immunology, Immunotherapy 3/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.